Maintenance Phase: What Happens After the Initial Weight Loss and How to Maintain Results:After the initial weight loss phase, the focus shifts to maintaining results and preventing weight gain

Risk factors that may influence the decision to pause treatment include: Being in the dose-escalation phase of GLP-1 therapy Experiencing active gastrointestinal symptoms (nausea, vomiting, bloating) Having known gastroparesis or other conditions affecting gastric emptying Taking concurrent medications that further delay gastric emptying (e.g., opioids) Undergoing procedures with higher aspiration risk (e.g., emergency surgery, airway surgery) If your anaesthetist or surgical team advises temporary cessation based on your individual risk assessment, the timing will depend on the specific medication: Daily injections (such as liraglutide): Typically paused 24 hours before surgery Weekly injections (such as semaglutide, dulaglutide): Often paused with the last dose given at least 7 days before surgery Oral semaglutide (Rybelsus): Usually paused 24 hours before surgery [4] However, these timings may vary according to local NHS Trust protocols and individual clinical assessment

Adding healthy mitochondria eradicates depression symptoms: Transplanting healthy mitochondria into the brains of mice cures depressive symptoms
Our case series obviously is not the prospective randomized controlled clinical trial which would be required to establish the clearest characterization of benefits from GLP-1RA therapy in MCAS
Tirzepatide can be a well-tolerated and extremely effective weight loss treatment option for overweight and obese adults
The WEGOVY pill is a peptide-based molecule (semaglutide) that requires an absorption enhancer (SNAC) and must be taken fasting, 30 minutes before eating or drinking anything other than water